Research News

By protecting the brain from shrinkage, aerobic exercise may slow the progression of Parkinsons disease, a progressive disorder of the nervous system, says a neurologist.In an editorial published online in the journal JAMA Neurology, neurologist J Eric Ahlskog from Mayo Clinic in Minnesota recommends that modern physical therapy practices should incorporate aerobic exercise training and encourage fitness for patients with Parkinson's disease.

A team of neurosurgeons and engineers has developed wireless brain sensors that monitor pressure and temperature inside the brain and then are absorbed by the body so that there is no need for surgery to remove the devices.

Two consecutive nights of “catch up” sleep on the weekend may reverse the increased risk of diabetes associated with short-term sleep deficit during the work week, suggests new research.

A novel light-activated nanotherapy developed by researchers at the University of Colorado- Boulder may be an effective weapon against the drug-resistant bacteria, say researchers including one of Indian-origin.

Cranberry extracts can help fighting urinary tract infections (UTIs) or bladder infection in breast-fed babies less than one year of age, new research says

[adsense:336x280:8701650588]

Greater intake of dietary nitrate and green leafy vegetables is associated with a 20-30 percent lower risk of primary open-angle glaucoma (POAG), according to a study.

The US Food and Drug Administration cleared the Olympus TJF-Q180V duodenoscope with modifications to the device’s design and labeling intended to help reduce the risk of bacterial infections. Olympus will voluntarily recall its original model currently being used in health care facilities and make the needed repair as quickly as possible.

Heron Therapeutics, Inc., announced that the U.S. Food and Drug Administration (FDA) has informed the Company that it has not yet completed its review of the New Drug Application (NDA) of SUSTOL® (granisetron) Injection,extended release and would not be taking action by the Prescription Drug User Fee Act (PDUFA) goal date of January 17, 2016 and anticipates taking action in late February 2016.

Nivalis Therapeutics, Inc., a clinical stage pharmaceutical company focused on developing innovative solutions for people with cystic fibrosis (“CF”),  announced the U.S. Food and Drug Administration ("FDA") has granted Orphan Drug Designation to the Company's lead investigational drug, N91115, a novel stabilizer of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.

Researchers are likely to have uncovered a novel mechanism behind the ability of the common diabetes drug - metformin -- to inhibit the progression of pancreatic cancer.